A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications
Principal Investigator
Ric ProcyshynOverview
Body Locations and Systems
BrainDisorders and Conditions
Mental HealthClinicalTrials.gov#
NCT02213887Status
Closed for RecruitmentStudy Start/End
Sep 1, 2014 to Mar 21, 2017Locations
St. Paul's Hospital, UBC Hospital
Name/Title
Heidi Boyda, Post Doctoral FellowPhone
604-822-7500Email Address
hnboyda@gmail.comPurpose of Study
The purpose of this 9-day study is to determine if:
- Pantoprazole modifies the steady-state plasma concentrations of orally administered psychotropic medications including valproic acid, lithium, and second-generation antipsychotics (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)
- Serum gastrin levels change within a week of starting or stopping pantoprazole
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.